8-K: Eli Lilly Anticipates Strong 2025 Revenue Growth Driven by New Medicines and Market Expansion

Eli Lilly projects substantial revenue growth for 2025, driven by new product launches and increased demand for existing medications, while also updating its 2024 revenue expectations.

Summary

• Eli Lilly expects full-year 2024 revenue to be approximately $45.0 billion, a 32% increase compared to the previous year.
• Q4 2024 revenue is projected to be around $13.5 billion, a 45% increase compared to Q4 2023, including $3.5 billion from Mounjaro and $1.9 billion from Zepbound.
• The company anticipates 2025 revenue to range from $58.0 billion to $61.0 billion, representing a 32% growth at the midpoint compared to the expected 2024 revenue.
• The 2024 revenue is expected to be $400 million below the previously issued guidance due to slower-than-anticipated growth in the U.S. incretin market and lower channel inventory.
• Lilly expects revenue growth in 2025 to be driven by new medicines like Jaypirca, Ebglyss, Omvoh, and Kisunla, as well as new indications for existing medicines and the launch of Mounjaro in additional markets.
• The company plans to increase its production of salable doses of incretins by at least 60% in the first half of 2025 compared to the first half of 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong revenue growth projections for 2025 and the success of new drugs like Mounjaro and Zepbound, but tempered by the slight miss in 2024 revenue guidance.

Positives

• The company expects strong revenue growth in 2024 and 2025.
• New medicines and indications are expected to contribute to revenue growth in 2025.
• Increased manufacturing capacity is expected to alleviate supply constraints.
• Mounjaro and Zepbound are experiencing robust sales growth.
• Non-incretin revenue grew by 20% compared to Q4 2023.

Negatives

• The company's expected 2024 revenue is $400 million below the previous guidance range.
• Slower-than-anticipated growth in the U.S. incretin market and lower channel inventory contributed to the Q4 results.

Risks

• The preliminary financial information is unaudited and may change.
• The company faces risks related to the pharmaceutical research and development process, regulatory approvals, competition, pricing pressures, and product supply.
• Global macroeconomic conditions, fluctuations in foreign currency exchange rates, and changes in tax laws could impact results.
• Reliance on relatively few products or product classes for a significant percentage of the company's total revenue and an increasingly consolidated supply chain.

Future Outlook

Eli Lilly anticipates continued momentum in 2025 with strong financial and operational performance, driven by new medicines, new indications for existing medicines, and expansion into new markets.

Management Comments

• David A. Ricks, Lilly chair and CEO, stated that 2024 was a pivotal and highly successful year for Lilly and expects to continue the momentum in 2025.
• David A. Ricks noted that U.S. supply across all doses of tirzepatide was available throughout Q4.

Industry Context

The announcement highlights the increasing demand for incretin-based therapies like Mounjaro and Zepbound in the diabetes and weight management markets, reflecting a broader trend in the pharmaceutical industry towards innovative treatments for chronic diseases.

Comparison to Industry Standards

• Lilly's projected 32% revenue growth for 2024 significantly outpaces the average growth rate for large-cap pharmaceutical companies, which typically ranges from 5% to 10%.
• Competitors like Novo Nordisk (NVO) and Pfizer (PFE) are also focusing on incretin-based therapies and obesity treatments, but Lilly's Mounjaro and Zepbound are rapidly gaining market share.
• The expected $3.5 billion in Q4 2024 revenue from Mounjaro positions it as a leading drug in its class, comparable to Novo Nordisk's Ozempic in terms of market impact.
• Lilly's commitment to increasing incretin production by 60% in the first half of 2025 demonstrates a proactive approach to addressing supply chain challenges, a common issue in the pharmaceutical industry.

Stakeholder Impact

• Shareholders can expect continued growth and potential returns due to the company's strong financial performance.
• Employees may benefit from increased job security and opportunities due to the company's expansion.
• Customers will have access to innovative medicines for diabetes, obesity, and other health conditions.
• Suppliers may see increased demand for their products and services due to the company's increased production.

Next Steps

• The company plans to share its full Q4 2024 financial results and 2025 financial guidance on February 6, 2025.

Key Dates